BioSpace News Archive

In response to the WHO classifying COVID-19 as a pandemic, ej4 is offering new training content to help clients inform their employees about what coronavirus is, and how they can take precautionary measures to prepare for a pandemic situation.

Global and our affiliates have received numerous inquiries about whether or not people with Down syndrome are more at risk than typical people when it comes to exposure to the coronavirus disease (COVID-19)

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter and the full year ended December 31, 2019.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for 2019.

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced its financial results for the fourth quarter and year ended December 31, 2019, and provided a company update.

- VENCLYXTO® plus obinutuzumab is the first chemotherapy-free, fixed-duration combination regimen approved by the European Commission (EC) for patients with previously untreated chronic lymphocytic leukemia (CLL)

Thermo Fisher Scientific announced today it has signed an agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to co-develop a companion diagnostic (CDx) in oncology.

PolarityTE, Inc., today reported results for calendar fourth quarter and year ended December 31, 2019.

OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will report its fourth quarter and full year 2019 financial results after the close of the U.S. financial markets on Tuesday,

The biopharma successfully produced Virus-Like Particles (VLP) of the coronavirus in just 20 days using proprietary plant-based technology